'de novo' AMP biosynthetic process

Across TCGA pan-cancer cohorts, RNA activity of the 'de novo' AMP biosynthetic process pathway differs between tumor and matched normal tissue in 16 of the 18 cancer types tested.

The strongest signal is observed in colon adenocarcinoma (COAD), where pathway activity is higher in tumor tissue than in matched normal tissue. In most cancer types, this pathway shows higher activity in tumors, although a few cancer types, such as THCA and KICH, show the opposite pattern, with lower activity in tumor tissue.

COAD, HNSC, and KIRC show the most reproducible tumor–normal differences in pathway activity.

Tumor vs normal pathway activity by lineage

Ranked by sampling consensus. Activity change represents the tumor-versus-normal difference in pathway activity on a log₂ scale. Positive values indicate higher pathway activity in tumor tissue. The reported p-values are derived from the corresponding differential activity tests.

Lineage	Gender	Stage	Activity change	p	Sampling consensus
COAD	Female	III,IV	+0.160	<.001	12	view →
HNSC	All	All	+0.050	<.001	12	view →
KIRC	Female	II,III,IV	+0.064	<.001	11	view →
STAD	Female	All	+0.140	<.001	10	view →
LUAD	Male	All	+0.140	<.001	9	view →
BLCA	All	All	+0.077	<.001	9	view →
LUSC	Male	III,IV	+0.214	<.001	8	view →
UCEC	All	All	+0.074	<.001	6	view →
LIHC	All	All	+0.026	<.001	5	view →
BRCA	All	II,III,IV	+0.024	<.001	4	view →
THCA	Female	All	−0.022	<.001	4	view →
READ	All	All	+0.122	.001	3	view →

Pink = more active in tumor, green = less active in tumor. Showing the 12 strongest of 16 lineages.

GO:0044208–COAD

Open the COAD breakdown →